2024-02-20 イリノイ大学アーバナ・シャンペーン校
◆研究では、フィナステリドの使用とコレステロールの低下との間に有意な相関関係が見つかりました。また、マウスを対象とした実験では、高用量のフィナステリドを摂取することで、全体的なコレステロールの低下や動脈硬化の進行の遅延、肝臓の炎症の低下などの利点が見られました。これらの発見は臨床研究での検証が必要ですが、フィナステリドが心臓血管疾患の予防に役立つ可能性があることを示唆しています。
<関連情報>
- https://aces.illinois.edu/news/common-hair-loss-and-prostate-drug-may-also-cut-heart-disease-risk-men-and-mice
- https://www.sciencedirect.com/science/article/pii/S0022227524000129#abs0010
フィナステリドはマウスの動脈硬化の進行を遅らせ、男性の血漿コレステロールの減少と関連する Finasteride delays atherosclerosis progression in mice and is associated with a reduction in plasma cholesterol in men
Patrick McQueen , Donald Molina , Ivan Pinos , Samuel Krug , Anna J. Taylor , Michael R. LaFrano , Maureen A. Kane , Jaume Amengual
Journal of Lipid Research Available online 23 January 2024
DOI:https://doi.org/10.1016/j.jlr.2024.100507
Abstract
Finasteride is commonly prescribed to treat benign prostate hyperplasia and male-pattern baldness in cis men and, more recently, trans individuals. However, the effect of finasteride on cardiovascular disease remains elusive. We evaluated the role of finasteride on atherosclerosis using low-density lipoprotein (LDL) receptor-deficient (Ldlr-/-) mice. Next, we examined the relevance to humans by analysing the data deposited between 2009 and 2016 in the National Health and Nutrition Examination Survey (NHANES). We show that finasteride reduces total plasma cholesterol and delays the development of atherosclerosis in Ldlr-/- mice. Finasteride reduced monocytosis, monocyte recruitment to the lesion, macrophage lesion content, and necrotic core area, the latter of which is an indicator of plaque vulnerability in humans. RNA sequencing analysis revealed a downregulation of inflammatory pathways and an upregulation of bile acid metabolism, oxidative phosphorylation, and cholesterol pathways in the liver of mice taking finasteride. Men reporting the use of finasteride showed lower plasma levels of cholesterol and LDL-cholesterol than those not taking the drug. Our data unveil finasteride as a potential treatment to delay cardiovascular disease in people by improving the plasma lipid profile.
